http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 05 Aug 2026 06:50:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast at <chron>8:00 a.m. EDT</chron></i></p><p><span class="legendSpanClass">CARMIEL, <location value="LC/il" idsrc="xmltag.org" >Israel</location></span>, <span class="legendSpanClass"><chron>Aug. 5, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:PLX" idsrc="xmltag.org" >Protalix BioTherapeutics, Inc.</span> (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that it will release its financial results for the quarter ended <chron>June 30, 2026</chron> and provide a business update on <chron>August 12, 2026</chron>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Protalix+BioTherapeutics+to+Announce+Second+Quarter+2026+Financial+Results+and+Business+Update+on+August+12%2C+2026/26869852.html Wed, 05 Aug 2026 06:50:00 -0400 A.31523649 O.01383535 O.02989433 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+First+Quarter+2026+Financial+and+Business+Results/26481316.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Elfabrio commercial execution continues following <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span> approval of the 2 mg/kg every–4–weeks (E4W) dosing regimen; <money>$25 million</money> milestone received from Chiesi</li><li>PRX–115 Phase 2 study continues to advance as planned with top–line results anticipated in the second half of 2027</li><li>The Company reaffirms its previously stated 2026 revenue guidance of <money>$78.0</money> – <money>$83.0 million</money> including the <money>$25.0 million</money> milestone received from Chiesi</li><li>Cash, cash equivalents, and short–term bank deposits were <money>$51 million</money> as of <chron>March 31, 2026</chron>, providing sufficient capital to fund ongoing operations including the http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+First+Quarter+2026+Financial+and+Business+Results/26481316.html Wed, 13 May 2026 06:50:00 -0400 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50200961 A.50216777 A.60012004 O.00532504 O.01304637 O.01383535 O.02989433 O.20026344 O.22422661 O.54516537 PBD PBD PBDA PBDA PBDA PBDA PLX PLX US74365A30